{"created":"2023-06-19T11:39:55.508840+00:00","id":8157,"links":{},"metadata":{"_buckets":{"deposit":"fe6b512d-415d-4354-8e40-281dcd7eda5e"},"_deposit":{"created_by":15,"id":"8157","owners":[15],"pid":{"revision_id":0,"type":"depid","value":"8157"},"status":"published"},"_oai":{"id":"oai:mie-u.repo.nii.ac.jp:00008157","sets":["631:636:1692684632717"]},"author_link":["20287","20288","20285","20286"],"item_8_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-05-18","bibliographicIssueDateType":"Issued"}}]},"item_8_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"IWAMOTO, Takuya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"20287","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"OKUDA, Masahiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"20288","nameIdentifierScheme":"WEKO"}]}]},"item_8_description_14":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"白金系薬物は、繰り返し投与により重篤な過敏症を引き起こすことが知られている。また、白金系薬物であるカルボプラチンによる過敏症の既往のある患者では、末梢血のin vitroでのカルボプラチンの刺激により、好塩基球が活性化することが確認されている。本研究では、カルボプラチンによる好塩基球の活性化機序を解明するために、13名の患者（過敏症発症者5名、未発症者8名）を対象に研究を行った。その結果、カルボプラチンによる好塩基球の活性化はIgE依存性の反応であり、IgE受容体であるFcεRIの過剰発現を伴い反応性変化を引き起こすことが明らかとなった。","subitem_description_type":"Abstract"},{"subitem_description":"$$It is well known that platinum drugs induced severe hypersensitivity reaction (HR) after the repeated administration, and basophil activation was observed in patients with a history of carboplatin induced severe HR. However, the precise mechanism by which carboplatin induces basophil activation. To investigate whether IgE-dependent mechanisms, including the overexpression of FceRI, participate in carboplatin-induced basophil activation, 13 ovarian cancer patients were enrolled: 5 with a history of carboplatin-induced severe HR within the past 2 years, and 8 with no such history. Our results indicated that an IgE-dependent mechanism incorporating FceRI overexpression participates in carboplatin-induced severe HR.","subitem_description_type":"Abstract"}]},"item_8_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"2012年度～2014年度科学研究費補助金(基盤研究(C))研究成果報告書","subitem_description_type":"Other"}]},"item_8_description_64":{"attribute_name":"科研費番号","attribute_value_mlt":[{"subitem_description":"24590188","subitem_description_type":"Other"}]},"item_8_publisher_30":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"三重大学"}]},"item_8_text_18":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_text_value":"Risk evaluation of carboplatin-induced allergy based on basophil activation test and FceRI expression."}]},"item_8_text_65":{"attribute_name":"資源タイプ（三重大）","attribute_value_mlt":[{"subitem_text_value":"Kaken / 科研費報告書"}]},"item_8_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"岩本, 卓也","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"奥田, 真弘","creatorNameLang":"ja"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-02-18"}],"displaytype":"detail","filename":"39K17863.pdf","filesize":[{"value":"652.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"39K17863.pdf","url":"https://mie-u.repo.nii.ac.jp/record/8157/files/39K17863.pdf"},"version_id":"1abfaed3-032f-423f-ad3d-61926075aa54"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"好塩基球","subitem_subject_scheme":"Other"},{"subitem_subject":"バイオマーカー","subitem_subject_scheme":"Other"},{"subitem_subject":"カルボプラチン","subitem_subject_scheme":"Other"},{"subitem_subject":"白金系抗がん薬","subitem_subject_scheme":"Other"},{"subitem_subject":"アレルギー","subitem_subject_scheme":"Other"},{"subitem_subject":"IgE","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"白金系抗がん薬の過敏症発現機序に基づく再投与可能患者の選別法構築","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"白金系抗がん薬の過敏症発現機序に基づく再投与可能患者の選別法構築","subitem_title_language":"ja"}]},"item_type_id":"8","owner":"15","path":["1692684632717"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2017-01-13"},"publish_date":"2017-01-13","publish_status":"0","recid":"8157","relation_version_is_last":true,"title":["白金系抗がん薬の過敏症発現機序に基づく再投与可能患者の選別法構築"],"weko_creator_id":"15","weko_shared_id":-1},"updated":"2023-08-30T06:21:36.390209+00:00"}